Starpharma receives TGA approval for VivaGel

Company News

by Jessica Amir

A developer of dendrimer products, Starpharma (ASX:SPL) has received Australian marketing approval from the Therapeutic Goods of Administration (TGA) for its product, VivaGel, that treats bacterial vaginosis.

Starpharma’s VivaGel is now expected to be available in pharmacies in the new year.

The product developed by Starpharma, will be marketed by Aspen Pharmacare as Fleurstat BV gel, carrying the VivaGel brand.

Aspen will also promote and distribute the product to clinicians and pharmacies in Australia and New Zealand.

Shares in Starpharma (ASX:SPL) are trading 3.36 per cent higher to $1.39.

 

Jessica Amir

Finance News Network
Jessica joined FNN in January 2017 after having worked in financial advising for seven years and in TV journalism for seven years, specialising in finance, equities and analysis. She has interviewed former Prime Ministers of Australia, Tony Abbott, Julia Gillard and Kevin Rudd and ex Treasurer Jo Hockey. Jessica has worked as a journalist with Sky News Business, ABC 1, ABC's The Business, ABC24 and has also been a regional Channel 7 and 9 TV reporter with Prime7 and Win News.